Healthcare Industry News: radiosurgery
News Release - June 6, 2018
FlexDex, Inc. Appoints New Vice President, Research and Development and Vice President, International Sales and MarketingBRIGHTON, Mich., June 06, 2018 -- (Healthcare Sales & Marketing Network) -- FlexDex, Inc. (“FlexDex” or “Company”), a medical device company that is developing a platform of articulating laparoscopic instruments for minimally invasive surgery, announced today the addition of two seasoned medical device executives. James Bertolina, PhD, has joined the Company as Vice President of Research and Development and Kin Cheung has joined the Company as Vice President, International Sales and Marketing.
Dr. Bertolina will be responsible for managing the design and development of the Company’s innovative products and growing the Company’s technology and IP portfolio. Dr. Bertolina brings over 20 years of experience in medical device product innovation and research, including nine years with HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy.
After co-founding HistoSonics in 2009, Dr. Bertolina served as Chief Technology Officer for eight years and most recently as Chief Scientific Officer, leading all product development and research efforts during that time. Dr. Bertolina directed the development of HistoSonics’ innovative therapeutic device used in a great number of preclinical applications, and was responsible for growing HistoSonics’ impressive IP and trade secret portfolio. Prior to this time, Dr. Bertolina served as Vice President, New Product Development at Xoran, Inc., Technical Director for the Stryker Navigation System at Stryker, Inc., and a Medical Physicist specializing in radiosurgery at Leibinger, Inc.
“We are very pleased to welcome Jim to the FlexDex team. We expect that Jim’s significant experience in medical device product innovation and research will be a valuable asset as we continue to develop and expand our platform of articulating laparoscopic instruments,” stated Dr. Shorya Awtar, Co-founder and Chief Technology Officer at FlexDex.
Dr. Bertolina earned his BS and MS, both in Physics, from the University of Utah. He received his PhD and completed a postdoc in Medical Physics Research (Radiology and Radiotherapy) at the University of Virginia.
Mr. Cheung will be responsible for the planning and execution of several key areas of the Company’s overall global sales and marketing initiatives and will be vital in supporting the Company’s mission to enable minimally invasive surgery in any operating room, anytime of day, anywhere in the world. Mr. Cheung brings over 10 years of experience in developing medical device businesses in Asia, including three years with Global Link Medical Consulting & Distribution, LLC, that specializes in helping innovative medical device companies expand their business in Asia by creating a comprehensive go-to market strategy.
Prior to joining Global Link, Mr. Cheung served as Director, Sales and Clinical Marketing, Asia Pacific at Intuitive Surgical, Inc. where he was responsible for managing direct and indirect sales and marketing channels in Asia. Mr. Cheung also previously served as Global Product Director, Global Product Development, Global Marketing at Ethicon Endo-Surgery, Inc., J&J where he managed a portfolio of surgical stapling devices with annual worldwide revenue of $260 Million.
“Kin brings a wealth of experience and enthusiasm to this newly created strategic position," said Dr. James Geiger, Chief Executive Officer of FlexDex, Inc. "I am confident that his broad experience and strong leadership will help maximize sales of the FlexDex platform internationally.”
Mr. Cheung earned his BA, Mechanical Engineering, Mathematics, Physics from Wichita State University. His credentials also include Board Member and Business Secretary General for the Asian Pacific Prostate Society.
About FlexDex, Inc.
FlexDex is a medical device company that is developing the FlexDex platform to provide surgeons with high performance and cost effective minimally invasive surgical instruments. The Company’s focus is to enable advanced minimally invasive procedures with greater precision and efficiency bringing the benefits of minimally invasive surgery to patients throughout the world. FlexDex was developed at the University of Michigan by co-founders Shorya Awtar, Sc.D., James Geiger, MD and Greg Bowles. This platform technology enables highly intuitive, one-to-one mapping of the surgeon’s arm and hand motions to the articulating instrument inside the patient’s body. The patented “Virtual Center™” of the FlexDex platform is a simple mechanical design that, we believe, will greatly enhance the capabilities of all Minimally Invasive Surgical (MIS) instruments. The FlexDex Needle Driver, the first instrument of the FlexDex platform, has been granted the CE mark and is available for sale in the United States and internationally.
For more information, please visit the Company’s website at www.flexdex.com.
Forward Looking Statement
This press release includes forward-looking statements on FlexDex’s current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes,“ "estimates,” “indicates,” and similar expressions. These statements are based upon management’s current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. The information in this press release is provided only as of the date presented, and FlexDex undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.